The Lebanese Ministry of Health launched on 14 September 2022, the Lebanese National Pharmacovigilance System and the MEDSAFETY mobile application, which has been supported by the WHO for the last 10 years.

The purpose of the WHO's support for the pharmacovigilance system in Lebanon is to provide access to safe and effective drugs and vaccines. This pharmacovigilance system played a significant role in registering COVID-19 and vaccine adverse events following immunization (AEFI), which were registered at the WHO-Uppsala Medical Centre "VIGIFLOW" system.

Dr Abdinasir Abubakar, WHO Representative in Lebanon, stated, "A health care system that incorporates pharmacovigilance increases the safety of pharmaceuticals by reducing the incidence of adverse drug reactions and by providing a warning network for health care professionals, regulators, manufacturers, and consumers to take corrective actions in a timely and organized manner."

The system of pharmacovigilance is supported by generous funds from the EU.

Within the same scope, WHO is enhancing the automation of several systems and software at the Ministry of Public Health, in particular the Logistic Management System, the national 2D barcode system Meditrack, and the Supply Trace system for implanted medical devices.